Liver X receptor modulators: A review of recently patented compounds (2007-2009)

Expert Opinion on Therapeutic Patents

Volumn 20, Issue 4, 2010, Pages 535-562

  Li, Xiaolin ^a   Yeh, Vince ^a   Molteni, Valentina ^a  

^a GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION   (United States)

Author keywords

Atherosclerosis; ATP binding cassette transporter A1; Cardiovascular diseases; Liver X receptors; Reverse cholesterol transport; Triglyceride

Indexed keywords

3 [3 [[2 CHLORO 3 (TRIFLUOROMETHYL)BENZYL](2 DIPHENYLETHYL)AMINO]PROPOXY]PHENYLACETIC ACID; IMIDAZOLE DERIVATIVE; ISOXAZOLE DERIVATIVE; LIVER X RECEPTOR; LIVER X RECEPTOR AGONIST; LIVER X RECEPTOR ALPHA; LXR 623; N (2,2,2 TRIFLUOROETHYL) N [4 [2,2,2 TRIFLUORO 1 HYDROXY 1 (TRIFLUOROMETHOXY)ETHYL]PHENYL]BENZENESULFONAMIDE; PYRAZOLE DERIVATIVE; SULFONAMIDE; TETRAHYDROISOQUINOLINE DERIVATIVE; UNCLASSIFIED DRUG; WAY 254011; XL 652;

ALLERGIC ENCEPHALOMYELITIS; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ATHEROSCLEROSIS; BINDING AFFINITY; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DRUG BINDING; DRUG EFFECT; DRUG INDICATION; DRUG STRUCTURE; HUMAN; LIPOGENESIS; LUPUS LIKE SYNDROME; MULTIPLE SCLEROSIS; NIEMANN PICK DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATENT; REVIEW; STRUCTURE ACTIVITY RELATION;

ANIMALS; ATHEROSCLEROSIS; CHOLESTEROL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; LIGANDS; LIPOGENESIS; ORPHAN NUCLEAR RECEPTORS; PATENTS AS TOPIC;

EID: 77949905582     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543771003621269     Document Type: Review

References (83)

1. Kalaany NY, Mangeksdorf DJ. LXRs and FXR: the yin and yang of cholesterol and fat metabolism. Annu Rev Physiol 2006;68:159-191
2. Tontonoz P, Mangelsdorf DJ. Liver x receptor signaling pathways in cardiovascular disease. Mol Endocrinol 2003;17:985-993
3. Joseph SB, Castrillo A, Laffitte BA, et al. Reciprocal regulation of inflammation and lipid metabolism by liver X receptors. Nat Med 2003;9:213-219
4. Schultz JR, Tu H, Luk A, et al. Role of LXRs in control of lipogenesis. Genes Dev 2000;14:2831-2838
5. Horton JD, Goldstein JL, Brown MS. SREBPs: transcriptional mediators of lipid homeostasis. Cold Spring Harb Symp Quant Biol 2002;67:491-498
6. Joseph SB, Laffitte BA, Patel PH, et al. Direct and indirect mechanisms for regulation of fatty acid synthase gene expression by liver X receptors. J Biol Chem 2002;277:11019-11025
7. Grefhorst A, Elzinga BM, Voshol PJ, et al. Stimulation of lipogenesis by pharmacologicalactivation of the liver X receptor leads to production of large, triglyceride-rich very low density lipoprotein particles. J Biol Chem 2002;277:34182-34190
8. Groot PHE, Pearc NJ, Yates JW, et al. Synthetic LXR agonists increase LDL in CETP species. J Lipid Res 2005;46:2182-2191
9. Quinet EM, Halpern AR, Basso MD, et al. A mixed LXR/PPARgamma/d agonist fails to rescue LXR-mediated dyslipidemia in a nonhuman primate model. In XIV International Symposium on Atherosclerosis; Rome, Italy; 2006
10. Lund EG, Menke JG, Sparrow CP. Liver X receptor agonists as potential therapeutic agents for dyslipidemia and atherosclerosis. Arterioscler Thromb Vasc Biol 2003;23:1169-1177
11. Lund EG, Peterson LB, Adams AD, et al. Different roles of liver X receptor alpha and beta in lipid metabolism: effects of an alpha-selective and a dual agonist in mice deficient in each subtype. Biochem Pharmacol 2006;71:453-463
12. Molteni V, Li X, Nabakka J, et al. N-Acylthiadiazolines, a new class of liver X receptor agonists with selectivity for LXRbeta. J Med Chem 2007;50:4255-4259
13. Peng D, Hiipakka RA, Dai Q, et al. Antiatherosclerotic effects of a novel synthetic tissue-selective steroidal liver X receptor agonist in low-density lipoprotein receptor-deficient mice. J Pharmacol Exp Ther 2008;327:332-342
14. Kratzer A, Buchebner M, Pfeifer T, et al. Synthetic LXR agonist attenuates plaque formation in apoEdeficient mice without inducing liver steatosis and hypertriglyceridemia. J Lipid Res 2009;50:312-326
15. Quinet EM, Savio DA, Halpern AR, et al. Geneselective modulation by a synthetic oxysterol ligand of the liver X receptor. J Lipid Res 2004;45:1929-1942
16. Quinet EM, Basso MD, Halpern AR, et al. LXR ligand lowers LDL cholesterol in primates, is lipid neutral in hamster, and reduces atherosclerosis in mouse. J Lipid Res 2009. [Epub ahead of print]
17. Katz A, Udata C, Ott E, et al. Safety, pharmacokinetics, and pharmacodynamics of single doses of LXR-623, a novel liver X-receptor agonist, in healthy participants. J Clin Pharm 2009;49:643-649
18. Repa JJ, Li H, Frank-Cannon TC, et al. Liver X receptor activation enhances cholesterol loss from the brain, decreases neuroinflammation, and increases survival of the NPC1 mouse. J Neurosci 2007;27:14470-14480
19. Ou X, Dai X, Long Z, et al. Liver X receptor agonist T0901317 reduces atherosclerotic lesions in apoE-/- mice by up-regulating NPC1 expression. Sci China C Life Sci 2008;51:418-429
20. Dai XY, Ou X, Hao XR, et al. The effect of T0901317 on ATP-binding cassette transporter A1 and Niemann-Pick type C1 in apoE-/- mice. J Cardiovasc Pharmacol 2008;51:467-475
21. Andersson S, Gustafsson N, Warner M, Gustafsson JA. Inactivation of liver X receptor beta leads to adult-onset motor neuron degeneration in male mice. Proc Natl Acad Sci USA 2005;102:3857-3862
22. Kim HJ, Fan X, Gabbi C, et al. Liver X receptor beta (LXRbeta): a link between beta-sitosterol and amyotrophic lateral sclerosis-Parkinson's dementia. Proc Natl Acad Sci USA 2008;105:2094-2099
23. Koldamova R, Lefterov I. Role of LXR and ABCA1 in the pathogenesis of Alzheimer's disease - implications for a new therapeutic approach. Curr Alzheimer Res 2007;4:171-178
24. Zelcer N, Khanlou N, Clare R, et al. Attenuation of neuroinflammation and Alzheimer's disease pathology by liver X receptors. Proc Natl Acad Sci USA 2007;104:10601-10606
25. Miller LJ, Chacko R. The role of cholesterol and statins in Alzheimer's disease. Ann Pharmacother 2004;38:91-98
26. Puglielli L, Tanzi RE, Kovacs DM. Alzheimer's disease: the cholesterol connection. Nat Neurosci 2005;6:345-351
27. Wolozin B. A fluid connection: cholesterol and Abeta. Proc Natl Acad Sci USA 2001;98:5371-5373
28. Du J, Chang J, Guo S, et al. ApoE 4 reduces the expression of Abeta degrading enzyme IDE by activating the NMDA receptor in hippocampal neurons. Neurosci Lett 2009;464:140-145
29. Fan J, Donkin J, Wellington C. Greasing the wheels of Abeta clearance in Alzheimer's disease: the role of lipids and apolipoprotein E. Biofactors 2009;35:239-248
30. Jiang Q, Lee CY, Mandrekar S, et al. ApoE promotes the proteolytic degradation of Abeta. Neuron 2008;58:681-693
31. Riddell DR, Zhou H, Atchison K, et al. Impact of apolipoprotein E (ApoE) polymorphism on brain ApoE levels. J Neurosci 2008;28:11445-11453
32. Wahrle SE, Jiang H, Parsadanian M, et al. Deletion of Abca1 increases Abeta deposition in the PDAPP transgenic mouse model of Alzheimer disease. J Biol Chem 2005;280:43236-43242
33. Wahrle SE, Jiang H, Parsadanian M, et al. Overexpression of ABCA1 reduces amyloid deposition in the PDAPP mouse model of Alzheimer disease. J Clin Invest 2008;118:671-682
34. Riddell DR, Zhou H, Comery TA, et al. The LXR agonist TO901317 selectively lowers hippocampal Abeta42 and improves memory in the Tg2576 mouse model of Alzheimer's disease. Mol Cell Neurosci 2007;34:621-628
35. Koldamova RP, Lefterov IM, Staufenbiel M, et al. The liver X receptor ligand T0901317 decreases amyloid beta production in vitro and in a mouse model of Alzheimer's disease. J Biol Chem 2005;280:4079-4088
36. Lefterov I, Bookout AL, Wang Z, et al. Expression profiling in APP23 mouse brain: inhibition of Abeta amyloidosis and inflammation in response to LXR agonist treatment. Mol Neurodegener 2007;2:20
37. Vanmierlo T, Rutten K, Dederen J, et al. Liver X receptor activation restores memory in aged AD mice without reducing amyloid. Neurobiol Aging 2009. [Epub ahead of print]
38. Xu J, Wagoner G, Douglas JC, Drew PD. Liver X receptor agonist regulation of Th17 lymphocyte function in autoimmunity. J Leukoc Biol 2009;86:401-409
39. A-Gonzales N, Bensinger SJ, Hong C, et al. Apoptotic cells promote their own clearanceand immune tolerance through activation of the nuclear receptor LXR. Immunity 2009;31:245-258
40. Bennett DJ, Brown LD, Cooke AJ, et al. An update on non-steroidal liver X receptor agonists and their potential use in the treatment of atherosclerosis. Expert Opin Ther Patents 2006;16:1673-1699
41. Wrobel J, Steffan R, Bowen SM, et al. Indazole-based liver X receptor (LXR) modulators with maintained atherosclerotic lesion reduction activity but diminished stimulation of hepatic triglyceride synthesis. J Med Chem 2008;51:7161-7168
42. Wyeth. Cinnoline compounds and their use as liver X receptor modulators. WO094034; 2006
43. Hu B, Unwalla R, Collini M, et al. Discovery and SAR of cinnolines/ quinonlines as liver X receptor (LXR) agonists with binding selectivity for LXRbeta. Bioorg Med Chem Lett 2009;17:3519-3527
44. Hu B, Quinet E, Unwalla R, et al. Carboxylic acid based quinolines as liver X receptor modulators that have LXRbeta receptor binding selectivity. Bioorg Med Chem Lett 2008;18:54-59
45. Bernotas RC, Singhaus RR, Kaufman DH, et al. Biarylether amide quinolines as liver X receptor agonists. Bioorg Med Chem Lett 2009;17:1663-1670
46. Bernotas RC, Kaufman DH, Singhaus RR, et al. 4-(3-Aryloxyaryl)quinoline alcohols are liver X receptor agonists. Bioorg Med Chem Lett 2009;17:8086-8092
47. Wyeth. Quinoline compounds. WO049047; 2008
48. Bernotas RC, Kaufman DH, Singhaus RR, et al. 4-(3-Aryloxyaryl)quinoline sulfones are potent liver X receptor agonists. Bioorg Med Chem Lett 2010;20:209-212
49. Hu B, Bernotas RC, Unwalla R, et al. Quinoline-3-carboxamide containing sulfones as liver X receptor (LXR) agonists with binding selectivity for LXRbeta?and low blood-brain penetration. Bioorg Med Chem Lett 2010;20:689-693
50. Wyeth. Quinazoline compounds. WO020683; 2009
51. Wyeth. Benzimidazole compounds. WO086138; 2009
52. Travins JM, Bernotas RC, Kaufman DH, et al. 1-(3-Aryloxyaryl) benzimidazole sulfones are liver X receptor agonists. Bioorg Med Chem Lett 2010;20:526-530
53. Wyeth. Imidazole [1,2-A] pyridine compounds. WO086123; 2009
54. Singhaus RR, Bernotas RC, Steffan R, et al. 3-(3-Aryloxyaryl)imidazo[1,2- a] pyridine sulfones as liver X receptor agonists. Bioorg Med Chem Lett 2010;20:521-525
55. Wyeth. Imidazo [1,2-B] pyridazine compounds as modulators of liver X receptors. WO086130; 2009
56. Wyeth. Pyrazolo [1,5-A] pyrimidine compounds. WO086129; 2009
57. Wyeth Exelixis. Pyrazole based LXR modulators. WO002559; 2007
58. Wyeth Exelixis. Imidazole based LXR modulators. WO002563; 2007
59. Merck & Co. Therapeutic compounds for treating dyslipidemic conditions. WO081335A1; 2007
60. Merck & Co. Pyrazole amide derivatives, composition containing such compounds and methods of use. WO017055A2; 2006
61. Merck & Co. Substituted aryl and heteroaryl derivatives. WO102067A1; 2006
62. NV Organon. N-benzyl N¢-arylcarbonyl piperazine derivatives as LXR modulators. WO024550A1; 2009
63. F Hoffman-La Roche AG. Novel hexafluoroisopropanol substituted ether derivatives. US0074115A1; 2006
64. F Hoffman-La Roche AG. Novel hexafluoroisopropanol substituted cyclohexane derivatives. US0135601A1; 2006
65. F Hoffman-La Roche AG. Novel piperazine amide derivatives. WO021868A2; 2009
66. F Hoffman-La Roche AG. Biaryl sulfonamide derivatives. WO040289A2; 2009
67. Bristol-Myers-Squibb. Tetrahydroisoquinoline as LXR modulators. WO047991; 2007
68. Bristol-Myers-Squibb. LXR modulators. WO050425; 2007
69. AstraZeneca. Derivatives of isothiazol-3 (2H)-one 1,1-dioxides as liver X receptor modulators. WO073363; 2006
70. AstraZeneca. Derivatives of isothiazol-3 (2H)-thione 1,1-dioxides as liver X receptor modulators. WO073364; 2006
71. AstraZeneca. Non-anilinic derivatives of isothiazol-3(2H)-thione 1,1-dioxides as liver X receptor modulators. WO073365; 2006
72. AstraZeneca. Non-anilinic derivatives of isothiazol-3(2H)-one 1,1-dioxides as liver X receptor modulators. WO073366; 2006
73. AstraZeneca. 5-Thioxo-1, 5-dihydro-2H-pyrrol-2-one as liver X receptor modulators WO073367; 2006
74. Barry Forman. Synthetic ligands selective for LXRbeta over LXRalpha, identification and method of use thereof. US0030082; 2009
75. Kowa. Substituted carbinol compounds. WO065754; 2008
76. Kowa. LXR agonists. JP179562; 2008
77. IRM LLC & Novartis AG. Compounds and compositions as LXR modulators. WO092065; 2007
78. Naik SU, Wang X, Da Silva JS, et al. Pharmacological activation of liver X receptors promotes reverse cholesterol transport in vivo. Circulation 2006;13:90-97
79. Joseph SB, McKilligin E, Pei L, et al. Synthetic LXR ligand inhibits the development of atherosclerosis in mice. Proc Natl Acad Sci USA 2002;99:7604-7609
80. Levin N, Bischoff ED, Daige CL, et al. Macrophage liver X receptor is required for antiatherogenic activity of LXR agonists. Arterioscler Thromb Vasc Biol 2005;25:135-142
81. Tangirala RK, Bischoff ED, Joseph SB, et al. Identification of macrophage liver X receptors as inhibitors of atherosclerosis. Proc Natl Acad Sci USA 2002;99:11896-11901
82. Williams S, Bledsoe RK, Collins JL, et al. X-ray crystal structure of the liver X receptor beta ligand binding domain: regulation by a histidine-tryptophan switch. J Biol Chem 2003;278:27138-27143
83. Bradley MN, Hong C, Chen M, et al. Ligand activation of LXR beta reverses atherosclerosis and cellular cholesterol overload in mice lacking LXR alpha and apoE. Clin Invest 2007;117:2337-2346